Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down prior to trading on Tuesday . The stock had previously closed at $25.37, but opened at $23.7101. Chugai Pharmaceutical shares last traded at $23.81, with a volume of 27,262 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Smbc Nikko Sec. raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, Chugai Pharmaceutical has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Up 0.4%

The business has a fifty day simple moving average of $26.42 and a two-hundred day simple moving average of $27.37. The company has a market capitalization of $81.36 billion, a price-to-earnings ratio of 27.47 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.